查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1997357

临床试验药物供应和物流市场：按服务、采购模式、类型、交付方式、最终用户、治疗领域和临床试验阶段划分－2026-2032年全球市场预测

Clinical Trial Supply & Logistics Market by Services, Sourcing Model, Type, Mode of Delivery, End-user, Therapeutic Area, Phases of Clinical Trials - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年临床试验药物供应和物流市场价值为44.7亿美元，预计到2026年将成长至46.7亿美元，复合年增长率为5.98%，到2032年将达到67.2亿美元。

主要市场统计数据
基准年 2025 44.7亿美元
预计年份：2026年 46.7亿美元
预测年份 2032 67.2亿美元
复合年增长率 (%) 5.98%

现代临床试验药物供应和物流功能的综合框架，强调一体化运作、法规遵循和以病人为中心的执行。

临床试验供应和物流领域已发展成为一项策略职能，旨在支援试验的完整性、病患安全和法规遵循。近年来，其工作范围已从简单的运输协调扩展到温控配送、对照药物采购、复杂的包装和标籤以及全面的储存策略。因此，供应链团队现在是通讯协定设计、临床实验选择和病人参与策略中不可或缺的合作伙伴。这种范围的扩大要求临床运作、采购、外部生产和物流合作伙伴以及法规事务部门之间进行更高水准的协调。

临床试验供应链正在经历关键趋势的重塑，这些趋势的驱动力包括去中心化、治疗方法复杂性增加、数位化、监管协调以及对韧性的需求。

临床试验的供应和物流格局正在经历变革性变化，这主要受技术、监管和营运模式转变的驱动。首先，试验设计正变得更加以患者为中心和分散化，供应链也更加註重最后一公里配送、居家给药流程以及能够适应更广泛存储和处理场景的现场支援模式。因此，物流供应商和申办者正在投资于能够实现灵活路线规划、即时温度监控和完善的文件管理等能力，以确保在各种配送环节中维护完整的监管链。

评估 2025 年关税调整对采购决策、海关业务以及复杂产品组合的跨境临床物流的韧性的影响。

美国于2025年实施的新关税措施对临床试验供应链产生了累积影响，需要谨慎的策略性因应。对某些进口材料、组件和专用设备征收的关税增加了接收成本，迫使采购团队重新评估其全球筹资策略。此外，在规划跨国运输时，海关程序和合规义务变得更加关键，特别是对于需要严格文件记录和温度检验的管制药品和高度监管的组件而言。

细分市场主导的策略挑战：阐明服务、产品、交付、最终用户、治疗领域和阶段维度上的差异化营运、监管和采购要求。

从市场区隔观点理解市场，可以发现服务、采购、产品、交付、最终用户、治疗领域和阶段等各个维度上存在不同的营运需求和策略重点。就服务而言，在目标产品的每个阶段（采购、物流和配送、生产、包装、贴标和盲法、以及储存和保存），都需要独特的流程控制和供应商能力。具体而言，物流和配送可以分为低温运输和非低温运输配送，其中低温运输需要经过验证的容器、持续监控和专门的处理程序，这些都会影响包装设计和运输路线的选择。

针对临床试验用药供应的区域策略考量，重点在于主要全球市场的基础设施、监管复杂性和分销模式。

区域趋势在製定临床试验药物供应策略中发挥着至关重要的作用，因为不同地区的管理体制、基础设施成熟度和物流生态系统差异显着。在美洲，完善的低温运输基础设施和高度集中的后期临床试验活动使得平衡集中式库存中心与快速区域反应能力变得至关重要。该地区也为在市场附近采购对照药物和加快清关流程提供了机会，前提是文件和海关前程序协调得当。因此，许多申办者和服务供应商正优先考虑优化跨境运输路线，并投资建造区域仓储设施，以在不影响合规性的前提下缩短运输时间。

专注于竞争考察和基于能力的企业洞察、整合、专业化、数位化差异化以及塑造服务交付的伙伴关係策略。

关键的公司层面趋势揭示了每个市场参与企业如何定位自己以创造价值并降低客户风险。在製造、包装、低温运输物流和仓储方面拥有综合能力的服务供应商往往能为申办者提供简化的供应商管理和清晰的责任机制。同时，专注于特定领域的专家凭藉其在温度敏感型或高度监管产品方面的深厚技术专长而脱颖而出。物流专家与监管咨询公司之间的合作也日益普遍，从而能够实现更顺畅的清关流程和更快的临床实验场地推出。

为临床供应管理人员提供实用蓝图，以增强全球临床试验的韧性、可见性、采购柔软性、监管合规性和永续营运。

致力于加强临床试验供应和物流营运的产业领导者应采取一系列切实可行且优先排序的措施，以平衡短期连续性和长期韧性。首先，投资端到端视觉化工具，提供即时库存和环境监测。这些系统能够帮助采购、临床营运和法规遵循团队进行主动异常管理，并做出明智的决策。其次，对于关键物料和服务，应实施双重或多源采购策略，以最大限度地减少单点故障，并在合约条款中明确关税、清关和品质偏差方面的责任。

采用稳健的混合研究途径，结合专家访谈、监管分析和营运映射，以检验有关供应链的见解和建议。

本执行摘要的研究结合了对行业专家和从业人员的访谈、对公开法规和指南的严谨二手研究，以及对供应链行为的实践检验。主要资讯来源包括对供应链和临床营运高级领导、物流和包装合作伙伴的营运经理以及负责跨境合规的监管事务专家的结构化访谈。这些访谈旨在揭示与复杂治疗模式和分散式试验模式相关的通用挑战、成功的风险缓解策略以及新兴的能力需求。

为了支持可靠临床试验的实施，一项综合策略结论强调了可见性、管治、区域协调和韧性的必要性。

总之，目前临床试验的供应和物流需要一种适应性强、以证据为基础的方法，根据治疗方法的复杂性、监管差异的细微差别以及地域实际情况来客製化服务模式。投资于端到端可视性、检验的低温运输能力和灵活的采购系统的机构，更有能力应对日常营运波动和诸如关税制度变化等突发衝击。此外，从试验设计的早期阶段就纳入供应链考量，可以减少临时通讯协定变更，并实现更可预测的实施。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 临床试验药物供应与物流市场：依服务类型划分

  • 管制药物的采购
  • 物流/配送
    • 低温运输配送
    • 非低温运输配送
  • 製造业
  • 包装、标籤和遮蔽
  • 储存及储存期

第九章：临床试验药物供应与物流市场采购模式

  • 集中采购
  • 分散式采购

第十章 临床试验药物供应与物流市场：按类型划分

  • 生物製药
  • 医疗设备
  • 小分子药物

第十一章：以交付方式分類的临床试验药物供应和物流市场

  • 异地供应管理
  • 现场供应管理

第十二章 临床试验药物供应与物流市场：依最终使用者划分

  • 合约调查机构
  • 医疗设备製造商
  • 製药和生物技术公司

第十三章：临床试验药物供应与物流市场：依治疗领域划分

  • 血液疾病
  • 心血管疾病
  • 中枢神经系统和精神障碍
  • 皮肤病
  • 消化系统疾病
  • 耳鼻喉疾病
  • 免疫学
  • 感染疾病
  • 代谢性疾病
  • 肾臟病学
  • 肿瘤学
  • 罕见疾病
  • 呼吸系统疾病

第十四章 临床试验药物供应与物流市场：临床试验阶段

  • 学士/工程学士考试
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第十五章 临床试验药物供应与物流市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章 临床试验药物供应与物流市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 临床试验药物供应与物流市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国临床试验药物供应与物流市场

第十九章：中国临床试验药物供应与物流市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Acnos Pharma GmbH
  • ADAllen Pharma Ltd
  • Almac Group Limited
  • Ancillare, LP
  • Avantor, Inc.
  • Beroe Holdings Inc.
  • Biocair International Limited
  • Calyx
  • Catalent, Inc.
  • Clinical Services International LTD
  • Clinigen Group PLC
  • COREX LOGISTICS LIMITED
  • DHL Group
  • Eurofins Scientific SE
  • Experic, LLC
  • FedEx Corporation
  • ICON PLC
  • Inceptua SA
  • Infosys Limited
  • IPS Pharma
  • KLIFO A/S
  • Lonza Group AG
  • Marken Limited by United Parcel Service, Inc.
  • Microsoft Corporation
  • Myonex, Inc.
  • N-SIDE SA
  • NUVISAN GmbH
  • OCT Clinical GmbH
  • Octalsoft
  • Parexel International Corporation
  • PCI Pharma Services
  • PHOENIX Pharmahandel GmbH & Co KG
  • Piramal Pharma Limited
  • Recipharm AB
  • SAP SE
  • Sharp Services, LLC
  • Signant Health
  • SIRO Clinpharm Private Limited
  • Thermo Fisher Scientific Inc.
  • Tower Cold Chain Solutions
  • Uniphar PLC
  • Walden Group
  • Zuellig Pharma Pte Ltd by Interpharma Investments Limited
Product Code: MRR-501246436315

The Clinical Trial Supply & Logistics Market was valued at USD 4.47 billion in 2025 and is projected to grow to USD 4.67 billion in 2026, with a CAGR of 5.98%, reaching USD 6.72 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.47 billion
Estimated Year [2026] USD 4.67 billion
Forecast Year [2032] USD 6.72 billion
CAGR (%) 5.98%

Comprehensive framing of modern clinical trial supply and logistics functions emphasizing integrated operations, regulatory alignment, and patient-centric execution

The clinical trial supply and logistics domain has evolved into a strategic function that underpins trial integrity, patient safety, and regulatory compliance. Over recent years, the operational scope has extended beyond simple shipment coordination to encompass temperature-controlled distribution, comparator sourcing, packaging and labeling complexity, and comprehensive retention strategies. As a result, supply chain teams are now integral partners in protocol design, site selection, and patient engagement strategies. This expanded remit demands a higher degree of orchestration across clinical operations, procurement, external manufacturing and logistics partners, and regulatory affairs.

Consequently, organizations must reconcile competing priorities: accelerating timelines while safeguarding product quality and ensuring traceability across increasingly fragmented networks. The rise of biologics, complex devices, and personalized therapies further elevates cold chain and handling requirements, while site-level expectations grow as trials adopt decentralized elements. Facing these pressures, sponsors and their service providers are pivoting toward integrated models that blend centralized coordination with local execution capabilities to preserve control without sacrificing agility.

In this context, a clear understanding of service modalities, sourcing architectures, therapeutic and phase-based demands, and regional dynamics is essential. The following sections synthesize transformative market shifts, tariff implications, segmentation-level insights, and regional considerations that together inform strategic choices for leaders tasked with delivering safe, timely, and cost-efficient clinical supplies.

Key transformative trends reshaping clinical trial supply chains driven by decentralization, modality complexity, digitalization, regulatory harmonization, and resilience imperatives

The landscape of clinical trial supply and logistics is undergoing transformative shifts driven by technological, regulatory, and operational inflection points. First, trial designs have become more patient-centric and decentralized, prompting supply chains to prioritize last-mile delivery, home-based administration workflows, and site-support models that accommodate a wider range of storage and handling scenarios. As a consequence, logistics providers and sponsors are investing in capabilities that enable flexible routing, real-time temperature monitoring, and robust documentation to maintain chain-of-custody across disparate delivery touchpoints.

Simultaneously, the therapeutic mix is changing with an increasing share of complex modalities that require cold chain excellence and bespoke packaging solutions. This trend intensifies collaboration with specialized manufacturers and contract organizations to co-develop handling protocols and validation plans. In parallel, digitalization is reshaping inventory visibility through cloud-based track-and-trace platforms, predictive analytics for demand planning, and automated exception management to reduce waste and accelerate issue resolution.

Regulatory developments and heightened scrutiny of quality systems have also catalyzed process standardization and risk-based oversight across global operations. Accordingly, industry participants are adopting harmonized documentation practices and investing in training to ensure consistency across geographies. Finally, sustainability and resilience considerations have risen on executive agendas, prompting strategic shifts toward dual sourcing, regional manufacturing hubs, and transport-mode optimization to balance environmental goals with operational robustness. Together, these shifts redefine how supply chain teams plan, execute, and govern clinical logistics.

Assessment of how 2025 tariff adjustments have reshaped sourcing decisions, customs operations, and cross-border clinical logistics resilience across complex product portfolios

The introduction of updated tariff measures in the United States in 2025 has had a cumulative effect on clinical trial supply chains that demands measured strategic responses. Tariffs applied to select imported materials, components, and specialized equipment have increased landed costs and prompted procurement teams to reassess global sourcing strategies. Moreover, customs procedures and compliance obligations have become more consequential when planning multi-country shipments, especially for comparator products and highly regulated components that require strict documentation and validated temperature control.

Consequently, many organizations confronted with tariff-related cost pressure have accelerated initiatives to diversify supplier bases and evaluate regional manufacturing or finishing options to mitigate exposure. These responses are often accompanied by contractual renegotiations that shift certain risks and responsibilities between sponsors and service providers, and by a more rigorous total-cost-of-ownership approach in supplier selection. In addition, logistics planners are incorporating tariff sensitivity into scenario planning to anticipate duty changes and to identify transshipment or tariff-exemption opportunities where legally permissible.

Operationally, increased import scrutiny has also placed a premium on customs expertise and pre-clearance processes to avoid delays that could compromise product stability or study timelines. To manage these complexities, cross-functional teams are strengthening interfaces between regulatory, customs brokerage, and clinical supply planners, while also enhancing documentation controls to expedite inspections and clearances. Taken together, the tariff landscape has nudged the industry toward more resilient, regionally balanced supply architectures and toward tighter governance of cross-border movement for clinical materials.

Segment-driven strategic imperatives revealing differentiated operational, regulatory, and sourcing requirements across service, product, delivery, end-user, therapeutic, and phase dimensions

Understanding the market through a segmentation lens reveals differentiated operational requirements and strategic priorities across service, sourcing, product, delivery, end-user, therapeutic, and phase dimensions. When services are examined, comparator sourcing, logistics and distribution, manufacturing, packaging, labeling and blinding, and storage and retention each impose unique process controls and vendor capabilities. Specifically, logistics and distribution split into cold chain distribution and non-cold chain distribution, with cold chain requiring validated containers, continuous monitoring, and specialized handling protocols that change packaging design and transport lane selection.

Looking at sourcing model distinctions, centralized sourcing and decentralized sourcing create contrasting governance models. Centralized sourcing favors consolidation of supplier relationships, standardized contracts, and volume leverage, whereas decentralized sourcing emphasizes local responsiveness, site-level flexibility, and quicker reactivity to regional regulatory or logistical idiosyncrasies. These sourcing choices are further influenced by product type: biologic drugs, medical devices, and small molecules each present different stability profiles, handling tolerances, and regulatory documentation needs, thereby informing cold chain requirements, packaging complexity, and storage retention policies.

The mode of delivery-offsite supply management versus onsite supply management-shapes how inventory control and accountability are structured. Offsite models centralize custody with third-party logistics partners, enabling consolidated visibility and scalability, while onsite models integrate supply stewardship into clinical operations at trial sites, enhancing immediacy but requiring additional site-level training and oversight. End-user segmentation across contract research organisations, medical device companies, and pharmaceutical and biotechnology companies highlights varying procurement practices, contractual norms, and expectations for service-level agreements and quality documentation.

Therapeutic area differentiation also drives operational nuance: blood disorders, cardiovascular diseases, CNS and mental disorders, dermatological disorders, digestive disorders, ENT diseases, immunology, infectious diseases, metabolic disorders, nephrology, oncology, rare diseases, and respiratory disorders each correlate with unique dosing schemas, stability constraints, and patient interaction patterns that influence distribution cadence and packaging features. Finally, phases of clinical trials-BA/BE studies, Phase 1, Phase 2, Phase 3, and Phase 4-demand different scale, speed, and redundancy. Early phases frequently require small-batch manufacturing flexibility and rapid comparator access, while later phases emphasize scale-up, standardized processes, and robust retention samples for regulatory scrutiny. Integrating these segmentation perspectives enables tailored operational models that align service offerings with modality, market access strategy, and trial complexity.

Regional strategic considerations for clinical trial supply operations emphasizing infrastructure, regulatory complexity, and distribution models across key global markets

Regional dynamics play an outsized role in shaping clinical supply strategies because regulatory regimes, infrastructure maturity, and logistics ecosystems vary considerably across geographies. In the Americas, robust cold chain infrastructure and a high concentration of late-phase clinical activity make it critical to balance centralized inventory hubs with regional rapid-response capacity. This geography also presents opportunities for near-market comparator sourcing and expedited customs processes when documentation and pre-clearance are properly aligned. As a result, many sponsors and service providers prioritize cross-border lane optimization and invest in regional storage nodes to reduce transit times without compromising compliance.

Moving to Europe, the Middle East & Africa, complex regulatory mosaics and diverse logistical capabilities require nuanced planning. Europe's advanced manufacturing footprint and harmonized regulatory structures in many jurisdictions support an integrated approach to multi-country distribution, yet local labeling, language requirements, and national customs practices necessitate specialized labeling and packaging strategies. In contrast, several Middle Eastern and African markets present infrastructure limitations and regulatory variability that favor localized partnerships and contingency planning to maintain continuity.

Across the Asia-Pacific region, the rapid expansion of clinical trial activity, coupled with investments in manufacturing and logistics capacity, creates both opportunity and complexity. Regulatory modernization efforts in certain jurisdictions accelerate trial activation but also demand acute awareness of import controls, temperature excursions risks due to long transit distances, and site-level storage capabilities. Consequently, Asia-Pacific strategies often combine regional distribution centers with local finishing and labeling to maintain responsiveness while adhering to country-specific regulatory and quality expectations. Collectively, these regional insights underscore the importance of tailored supply architectures that reflect local realities while preserving global oversight and documentation consistency.

Competitive and capability-based company insights highlighting integration, specialization, digital differentiation, and partnership strategies shaping service delivery

Key company-level dynamics reveal how different market participants position themselves to capture value and reduce client risk. Service providers with integrated capabilities across manufacturing, packaging, cold chain distribution, and storage tend to offer sponsors simplified vendor management and clearer accountability, while niche specialists excel by delivering deep technical expertise for temperature-sensitive or highly regulated products. Partnerships between logistics experts and regulatory consultancies are becoming more common, enabling more seamless customs navigation and faster site activation timelines.

At the same time, contract manufacturers and contract research organizations that expand into adjacent services-such as clinical finishing, comparator sourcing, and labeling-create bundled offerings that reduce handoffs and the potential for transfer-related quality events. Conversely, some sponsors prefer to orchestrate a best-of-breed network that stitches together specialized vendors through rigorous governance and performance metrics. Across these models, investments in digital platforms for inventory visibility, exception management, and audit readiness are an area of differentiation among companies.

Moreover, companies that develop proprietary cold chain technologies, validated packaging formats, and robust temperature-monitoring ecosystems can accelerate client onboarding and reduce waste through improved predictability. Finally, strategic activities such as alliances, selective acquisitions, and co-investments in regional facilities reflect a market moving toward resilience and responsiveness. Collectively, these company insights spotlight the competitive contours and the operational choices firms make to support increasingly complex trial portfolios.

Practical roadmap for clinical supply leaders to enhance resilience, visibility, sourcing flexibility, regulatory alignment, and sustainable operations across global trials

Industry leaders seeking to strengthen clinical trial supply and logistics operations should adopt a set of actionable, prioritized measures that balance near-term continuity with long-term resilience. First, invest in end-to-end visibility tools that provide real-time inventory and environmental monitoring; these systems enable proactive exception management and informed decision-making across procurement, clinical operations, and regulatory teams. Second, implement dual or multi-sourcing strategies for critical materials and services to minimize single-point failures, complemented by contractual language that clarifies responsibilities for tariffs, customs, and quality deviations.

Third, modernize packaging and distribution strategies with validated cold chain solutions and contingency plans that include regional redistribution capabilities and controlled storage buffers. Fourth, align sourcing models with product complexity by selecting centralized governance for standardized SKUs and decentralized approaches for high-variation or regionally sensitive materials. Fifth, prioritize cross-functional governance forums that bring together supply chain, regulatory affairs, clinical operations, and legal to ensure that protocol and logistics design are synchronized from the outset.

Additionally, accelerate workforce development through targeted training in cold chain handling, customs compliance, and digital tools to close operational skill gaps at sites and within logistics partners. Emphasize sustainability by exploring lower-emission transport modes where feasible and by designing packaging with reduced material waste. Finally, embed scenario planning and tariff impact analyses into procurement workflows to anticipate policy shifts and to maintain agility in supplier selection and routing decisions. Taken together, these recommendations form a pragmatic roadmap for leaders to improve reliability, reduce operational friction, and sustain regulatory compliance.

Robust mixed-methods research approach combining expert interviews, regulatory analysis, and operational mapping to validate supply chain insights and recommendations

The research underpinning this executive summary combines primary engagement with industry experts and practitioners, rigorous secondary analysis of public regulation and guidance, and applied operational mapping to validate supply chain behaviors. Primary inputs included structured interviews with senior supply chain and clinical operations leaders, operational managers at logistics and packaging partners, and regulatory affairs specialists responsible for cross-border compliance. These conversations were designed to surface common pain points, successful mitigation strategies, and emergent capability requirements tied to complex modalities and decentralized trial models.

Secondary research drew on publicly available regulatory guidance, trade and customs documentation, and case examples of logistic innovations and cold chain validation protocols. In addition, operational mapping exercises reconstructed typical supply flows for various product categories and trial phases to identify critical control points, bottlenecks, and decision nodes where intervention yields disproportionate benefits. Validation steps included cross-referencing primary insights with documented regulatory requirements and with practitioner-validated checklists to ensure that recommendations are operationally feasible and compliant.

Finally, the methodology incorporated a synthesis stage where segmentation and regional variations were overlaid to produce tailored operational recommendations. Quality assurance measures for the research included peer review by subject-matter experts and iterative refinement based on stakeholder feedback to ensure clarity and applicability for decision-makers across procurement, clinical operations, and regulatory functions.

Consolidated strategic conclusions emphasizing the necessity of visibility, governance, regional calibration, and resilience to support reliable clinical trial execution

In conclusion, the current era of clinical trial supply and logistics demands an adaptive, evidence-based approach that aligns service models with therapeutic complexity, regulatory nuance, and geographic realities. Organizations that invest in end-to-end visibility, validated cold chain capabilities, and flexible sourcing architectures will be better positioned to manage both everyday operational variability and discrete shocks such as evolving tariff regimes. Moreover, integrating supply chain considerations into trial design from the earliest stages reduces last-minute protocol changes and drives more predictable execution.

Equally important is the intentional development of governance and talent to manage increasingly complex vendor ecosystems and to maintain audit readiness across jurisdictions. Regional strategies must be calibrated to local infrastructure and regulatory realities, and company-level choices between integrated and best-of-breed models should be informed by the specific modality and phase mix of the clinical portfolio. Finally, scenario planning and sustainability considerations should be embedded into procurement and logistics decisions to ensure that resilience and environmental objectives reinforce, rather than contradict, operational efficiency.

Taken together, these conclusions point to a strategic imperative: to view clinical trial supply and logistics as a differentiating capability that requires investment, cross-functional collaboration, and continuous refinement to support faster, safer, and more reliable clinical development.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Clinical Trial Supply & Logistics Market, by Services

  • 8.1. Comparator Sourcing
  • 8.2. Logistics & Distribution
    • 8.2.1. Cold Chain Distribution
    • 8.2.2. Non-Cold Chain Distribution
  • 8.3. Manufacturing
  • 8.4. Packaging, Labeling, & Blinding
  • 8.5. Storage & Retention

9. Clinical Trial Supply & Logistics Market, by Sourcing Model

  • 9.1. Centralized Sourcing
  • 9.2. Decentralized Sourcing

10. Clinical Trial Supply & Logistics Market, by Type

  • 10.1. Biologic Drugs
  • 10.2. Medical Devices
  • 10.3. Small Molecules

11. Clinical Trial Supply & Logistics Market, by Mode of Delivery

  • 11.1. Offsite Supply Management
  • 11.2. Onsite Supply Management

12. Clinical Trial Supply & Logistics Market, by End-user

  • 12.1. Contract Research Organisations
  • 12.2. Medical Devices Companies
  • 12.3. Pharmaceutical & Biotechnology Companies

13. Clinical Trial Supply & Logistics Market, by Therapeutic Area

  • 13.1. Blood Disorders
  • 13.2. Cardiovascular Diseases
  • 13.3. CNS & Mental Disorders
  • 13.4. Dermatological Disorders
  • 13.5. Digestive Disorders
  • 13.6. ENT Diseases
  • 13.7. Immunology
  • 13.8. Infectious Diseases
  • 13.9. Metabolic Disorders
  • 13.10. Nephrology
  • 13.11. Oncology
  • 13.12. Rare Diseases
  • 13.13. Respiratory Disorders

14. Clinical Trial Supply & Logistics Market, by Phases of Clinical Trials

  • 14.1. BA/ BE studies
  • 14.2. Phase 1
  • 14.3. Phase 2
  • 14.4. Phase 3
  • 14.5. Phase 4

15. Clinical Trial Supply & Logistics Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Clinical Trial Supply & Logistics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Clinical Trial Supply & Logistics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Clinical Trial Supply & Logistics Market

19. China Clinical Trial Supply & Logistics Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Acnos Pharma GmbH
  • 20.6. ADAllen Pharma Ltd
  • 20.7. Almac Group Limited
  • 20.8. Ancillare, LP
  • 20.9. Avantor, Inc.
  • 20.10. Beroe Holdings Inc.
  • 20.11. Biocair International Limited
  • 20.12. Calyx
  • 20.13. Catalent, Inc.
  • 20.14. Clinical Services International LTD
  • 20.15. Clinigen Group PLC
  • 20.16. COREX LOGISTICS LIMITED
  • 20.17. DHL Group
  • 20.18. Eurofins Scientific SE
  • 20.19. Experic, LLC
  • 20.20. FedEx Corporation
  • 20.21. ICON PLC
  • 20.22. Inceptua S.A.
  • 20.23. Infosys Limited
  • 20.24. IPS Pharma
  • 20.25. KLIFO A/S
  • 20.26. Lonza Group AG
  • 20.27. Marken Limited by United Parcel Service, Inc.
  • 20.28. Microsoft Corporation
  • 20.29. Myonex, Inc.
  • 20.30. N-SIDE SA
  • 20.31. NUVISAN GmbH
  • 20.32. OCT Clinical GmbH
  • 20.33. Octalsoft
  • 20.34. Parexel International Corporation
  • 20.35. PCI Pharma Services
  • 20.36. PHOENIX Pharmahandel GmbH & Co KG
  • 20.37. Piramal Pharma Limited
  • 20.38. Recipharm AB
  • 20.39. SAP SE
  • 20.40. Sharp Services, LLC
  • 20.41. Signant Health
  • 20.42. SIRO Clinpharm Private Limited
  • 20.43. Thermo Fisher Scientific Inc.
  • 20.44. Tower Cold Chain Solutions
  • 20.45. Uniphar PLC
  • 20.46. Walden Group
  • 20.47. Zuellig Pharma Pte Ltd by Interpharma Investments Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SERVICES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SOURCING MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MODE OF DELIVERY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASES OF CLINICAL TRIALS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COMPARATOR SOURCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COMPARATOR SOURCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COMPARATOR SOURCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COLD CHAIN DISTRIBUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COLD CHAIN DISTRIBUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COLD CHAIN DISTRIBUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY NON-COLD CHAIN DISTRIBUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY NON-COLD CHAIN DISTRIBUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY NON-COLD CHAIN DISTRIBUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PACKAGING, LABELING, & BLINDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PACKAGING, LABELING, & BLINDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PACKAGING, LABELING, & BLINDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY STORAGE & RETENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY STORAGE & RETENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY STORAGE & RETENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY CENTRALIZED SOURCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY CENTRALIZED SOURCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY CENTRALIZED SOURCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY DECENTRALIZED SOURCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY DECENTRALIZED SOURCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY DECENTRALIZED SOURCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY BIOLOGIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY BIOLOGIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MEDICAL DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MEDICAL DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY OFFSITE SUPPLY MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY OFFSITE SUPPLY MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY OFFSITE SUPPLY MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY ONSITE SUPPLY MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY ONSITE SUPPLY MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY ONSITE SUPPLY MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANISATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANISATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANISATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MEDICAL DEVICES COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MEDICAL DEVICES COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MEDICAL DEVICES COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY BLOOD DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY BLOOD DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY CNS & MENTAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY CNS & MENTAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY CNS & MENTAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY DERMATOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY DERMATOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY DERMATOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY DIGESTIVE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY DIGESTIVE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY DIGESTIVE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY ENT DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY ENT DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY ENT DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY NEPHROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY NEPHROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY NEPHROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY RESPIRATORY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY RESPIRATORY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASES OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY BA/ BE STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY BA/ BE STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY BA/ BE STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASE 1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASE 1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASE 1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASE 2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASE 2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASE 2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASE 3, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASE 3, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASE 3, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASE 4, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASE 4, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASE 4, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASES OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASES OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASES OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASES OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASES OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASES OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASES OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASES OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASES OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 198. GCC CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GCC CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 200. GCC CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 201. GCC CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 202. GCC CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. GCC CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 204. GCC CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 205. GCC CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 206. GCC CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASES OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASES OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASES OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 225. G7 CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. G7 CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 227. G7 CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 228. G7 CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 229. G7 CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. G7 CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 231. G7 CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 232. G7 CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 233. G7 CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASES OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 234. NATO CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. NATO CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 236. NATO CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 237. NATO CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 238. NATO CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. NATO CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 240. NATO CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 241. NATO CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 242. NATO CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASES OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASES OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY LOGISTICS & DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY SOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA CLINICAL TRIAL SUPPLY & LOGISTICS MARKET SIZE, BY PHASES OF CLINICAL TRIALS, 2018-2032 (USD MILLION)